Cardiotoxicity of Immune Checkpoint Inhibitors: Beyond Myocarditis

doi:10.1007/s13181-021-00851-6

Comment

. 2022 Jan;18(1):63-64.

doi: 10.1007/s13181-021-00851-6. Epub 2021 Jul 5.

Cardiotoxicity of Immune Checkpoint Inhibitors: Beyond Myocarditis

Demis N Lipe¹, Nicolas L Palaskas², Patrick Chaftari³

Affiliations

¹ Department of Emergency Medicine, Unit 1468, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Houston, TX, 77030, USA. DNLipe@mdanderson.org.
² Department of Cardiology, Unit 1451, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
³ Department of Emergency Medicine, Unit 1468, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Houston, TX, 77030, USA.

PMID: 34227031
PMCID: PMC8758869
DOI: 10.1007/s13181-021-00851-6

Comment

Cardiotoxicity of Immune Checkpoint Inhibitors: Beyond Myocarditis

Demis N Lipe et al. J Med Toxicol. 2022 Jan.

. 2022 Jan;18(1):63-64.

doi: 10.1007/s13181-021-00851-6. Epub 2021 Jul 5.

Authors

Demis N Lipe¹, Nicolas L Palaskas², Patrick Chaftari³

Affiliations

¹ Department of Emergency Medicine, Unit 1468, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Houston, TX, 77030, USA. DNLipe@mdanderson.org.
² Department of Cardiology, Unit 1451, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
³ Department of Emergency Medicine, Unit 1468, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Houston, TX, 77030, USA.

PMID: 34227031
PMCID: PMC8758869
DOI: 10.1007/s13181-021-00851-6

No abstract available

Keywords: Cardiotoxicity; Immune checkpoint inhibitors; irAEs, emergency department.

PubMed Disclaimer

Conflict of interest statement

DNL has received compensation for being a content expert for the Society of Immunotherapy of Cancer. DNL has also received compensation for multiple immunotherapy toxicity presentations from the PeerView Institute for Medical Education. The rest of the authors declare no conflicts of interest in this study.

Comment on

A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.
Chhabra N, Kennedy J. Chhabra N, et al. J Med Toxicol. 2021 Oct;17(4):411-424. doi: 10.1007/s13181-021-00833-8. Epub 2021 Apr 7. J Med Toxicol. 2021. PMID: 33826117 Free PMC article. Review.

References

1. Chhabra N, Kennedy J. A review of cancer immunotherapy toxicity: immune checkpoint inhibitors. J Med Tox. 2021; 10.1007/s13181-021-00833-8. - PMC - PubMed
1. Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140(2):80–91. doi: 10.1161/CIRCULATIONAHA.118.034497. - DOI - PMC - PubMed
1. Lipe DN, Galvis-Carvajal E, Rajha E, Wechsler AH, Gaeta S. Immune checkpoint inhibitor-associated myasthenia gravis, myositis and myocarditis overlap syndrome. Am J Emerg Med. 2021;46:51–55. doi: 10.1016/j.ajem.2021.03.005. - DOI - PubMed
1. Arora P, Talamo L, Dillon P, Gentzler RD, Millard T, Salerno M, et al. Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series. Cardiooncology. 2020;6:21. - PMC - PubMed
1. Zhan L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity. JACC CardioOnc. 2021;3(1):35–47. doi: 10.1016/j.jaccao.2020.11.012. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources

[1] Chhabra N, Kennedy J. A review of cancer immunotherapy toxicity: immune checkpoint inhibitors. J Med Tox. 2021; 10.1007/s13181-021-00833-8. - PMC - PubMed

[2] Chhabra N, Kennedy J. A review of cancer immunotherapy toxicity: immune checkpoint inhibitors. J Med Tox. 2021; 10.1007/s13181-021-00833-8. - PMC - PubMed

[3] Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140(2):80–91. doi: 10.1161/CIRCULATIONAHA.118.034497. - DOI - PMC - PubMed

[4] Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140(2):80–91. doi: 10.1161/CIRCULATIONAHA.118.034497. - DOI - PMC - PubMed

[5] Lipe DN, Galvis-Carvajal E, Rajha E, Wechsler AH, Gaeta S. Immune checkpoint inhibitor-associated myasthenia gravis, myositis and myocarditis overlap syndrome. Am J Emerg Med. 2021;46:51–55. doi: 10.1016/j.ajem.2021.03.005. - DOI - PubMed

[6] Lipe DN, Galvis-Carvajal E, Rajha E, Wechsler AH, Gaeta S. Immune checkpoint inhibitor-associated myasthenia gravis, myositis and myocarditis overlap syndrome. Am J Emerg Med. 2021;46:51–55. doi: 10.1016/j.ajem.2021.03.005. - DOI - PubMed

[7] Arora P, Talamo L, Dillon P, Gentzler RD, Millard T, Salerno M, et al. Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series. Cardiooncology. 2020;6:21. - PMC - PubMed

[8] Arora P, Talamo L, Dillon P, Gentzler RD, Millard T, Salerno M, et al. Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series. Cardiooncology. 2020;6:21. - PMC - PubMed

[9] Zhan L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity. JACC CardioOnc. 2021;3(1):35–47. doi: 10.1016/j.jaccao.2020.11.012. - DOI - PMC - PubMed

[10] Zhan L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity. JACC CardioOnc. 2021;3(1):35–47. doi: 10.1016/j.jaccao.2020.11.012. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Cardiotoxicity of Immune Checkpoint Inhibitors: Beyond Myocarditis

Affiliations

Cardiotoxicity of Immune Checkpoint Inhibitors: Beyond Myocarditis

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources